PD-L1 in Patients with Resected Non-small Cell Lung Cancer

Yoshihisa Shimada (  zenkyu@za3.so-net.ne.jp ) Tokyo Medical University Jun Matsubayashi Tokyo Medical University Yujin Kudo Tokyo Medical University Sachio Maehara Tokyo Medical University Susumu Takeuchi Tokyo Medical University Masaru Hagiwara Tokyo Medical University Masatoshi Kakihana Tokyo Medical University Tatsuo Ohira Tokyo Medical University Toshitaka Nagao Tokyo Medical University Norihiko Ikeda Tokyo Medical University

[1]  H. Kenmotsu,et al.  PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. , 2020, Japanese journal of clinical oncology.

[2]  F. Tanaka,et al.  Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung , 2020, Scientific Reports.

[3]  G. Freeman,et al.  The importance of exosomal PDL1 in tumour immune evasion , 2020, Nature Reviews Immunology.

[4]  Yan-Ze Jin,et al.  Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. , 2019, Journal of thoracic disease.

[5]  T. Lv,et al.  Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients , 2019, Journal of Translational Medicine.

[6]  Ce Li,et al.  Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis , 2019, Annals of Surgical Oncology.

[7]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[8]  K. Shimizu,et al.  Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer , 2019, Therapeutics and clinical risk management.

[9]  R. Blelloch,et al.  Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory , 2019, Cell.

[10]  E. Jaffee,et al.  PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. , 2019, JCI insight.

[11]  L. Landi,et al.  Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer , 2019, Oncotarget.

[12]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Barlesi,et al.  The clinical utility of tumor mutational burden in non-small cell lung cancer. , 2018, Translational lung cancer research.

[14]  R. Boidot,et al.  Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy , 2018, British Journal of Cancer.

[15]  Kongming Wu,et al.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular Cancer.

[16]  A. Ceribelli,et al.  Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC , 2018, AntiCancer Research.

[17]  Wei Zhang,et al.  Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response , 2018, Nature.

[18]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Ji-Young Hong,et al.  The role of exosomes and miRNAs in drug‐resistance of cancer cells , 2017, International journal of cancer.

[20]  F. Grossi,et al.  Exosomes: a new horizon in lung cancer. , 2017, Drug discovery today.

[21]  J. Pignon,et al.  PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Y. Murakumo,et al.  Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer , 2017, Oncology.

[23]  Y. Maehara,et al.  The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. , 2017, Lung cancer.

[24]  Masato Takahashi,et al.  The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) , 2017, Breast Cancer.

[25]  Andreas Möller,et al.  The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes. , 2016, Cancer research.

[26]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[27]  Jinming Yu,et al.  Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions , 2016, Oncotarget.

[28]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[29]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[30]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[31]  J. Madore,et al.  PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. , 2015, Lung cancer.

[32]  Michael A. Hollingsworth,et al.  Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.

[33]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[34]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[35]  H. Ditzel,et al.  Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[36]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  A. Dutt,et al.  Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity , 2013, PloS one.

[38]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[39]  Raghu Kalluri,et al.  Exosomes in tumor microenvironment influence cancer progression and metastasis , 2013, Journal of Molecular Medicine.

[40]  Gema Moreno-Bueno,et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2012, Nature Medicine.

[41]  E. Ruffini,et al.  Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. , 2009, The Annals of thoracic surgery.

[42]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.